FDA warns Dr. Daniel Fred Goodman/Goodman Eye Center over clinical drug study without required FDA application and missing consent/assent.
What happened
FDA inspected the clinical site between November 29 and December 13, 2021, and reviewed Dr. Goodman's conduct as sponsor-investigator of a clinical investigation of an investigational drug. FDA found the investigation began before an Investigational New Drug application (IND) was in effect, with four subjects enrolled and treated from September 17 to October 1, 2019. FDA also found two subjects enrolled without legally effective written consent and six minors enrolled without IRB-required written assent (a child's agreement).
What FDA found
Started a clinical investigation of an investigational drug before submitting an IND and having it in effect.
21 CFR 312.20(a), 312.20(b), and 312.40(a)Enrolled and treated four human subjects before the IND's effective date.
21 CFR 312.40Failed to obtain legally effective written informed consent from two subjects before enrolling them.
21 CFR 312.60, 50.20, and 50.27Failed to obtain the IRB-required written assent of six minors before enrolling them.
21 CFR 312.60 and 50.55
What FDA wants
Within 15 business days of receiving the letter, notify FDA in writing of actions taken to prevent similar violations and address the deficiencies. Failure to adequately address the matter may lead to regulatory action.
Who should pay attention
- sponsor-investigators running clinical trials
- IRBs and research sites enrolling minors
- contract research organizations and study coordinators
This is a summary. Read the original letter on fda.gov.